medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 5

<< Back Next >>

Ann Hepatol 2015; 14 (5)

Liver-specific case fatality due to chronic hepatitis C virus infection: a systematic review

Szabo SM, Samp JC, Walker DR, Lane S, Cline SK, Gooch KL, Jimenez-Mendez R, Levy AR

Language: English
References: 46
Page: 618-630
PDF size: 129.47 Kb.


ABSTRACT

Despite reports that mortality is increasing, overall case fatality due to hepatitis C virus (HCV) is thought to be low. Given the variability in published rates, we aimed to synthesize estimates of liver-specific case fatality and all-cause mortality in chronic HCV according to follow-up duration, sustained viral response (SVR) to treatment, and liver disease severity. A systematic review was conducted of studies published in English from 2003 to 2013, reporting liver-specific case fatality estimates from HCV-infected samples. Thirty-five eligible articles were identified; 26 also presented estimates of all-cause mortality. Among community-based samples, liver-specific case fatality ranged from 0.3% over 5.7 years to 9.2% over 8.2 years of follow-up; and of all-cause mortality, from 4.0% over 5.7 years, to 23.0% over 8.2 years of follow-up. Estimates were higher among clinic-based samples and those with more severe liver disease. Among treated patients achieving SVR, liver-specific case fatality was low: up to 1.4% over 11.5 years of follow-up among samples with any severity of liver disease. Estimates were higher among those without SVR: up to 14.0% over 10 years of followup among samples with any severity of liver disease, and higher still among samples with more severe liver disease. The proportion of deaths attributable to liver-specific causes ranged from 55 to 85% among those with severe liver disease. Published estimates of fatality are high among certain populations of chronic HCV patients, with liver-specific causes being an important contributor. Understanding current HCV mortality rates is important for quantifying the total burden of HCV disease.


REFERENCES

  1. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271-8.

  2. Thein H-H, Yi Q, Dore GJ, Krahn MD. Estimation of Stage- Specific Fibrosis Progression Rates in Chronic Hepatitis C Virus Infection: A Meta-Analysis and Meta-Regression. Hepatology 2008; 48: 418-31.

  3. Porta M. A Dictionary of Epidemiology. 5th Ed. New York: Oxford University Press Ubc; 2008.

  4. Uhanova J, Tate RB, Tataryn DJ, Minuk GY. A populationbased study of the epidemiology of hepatitis C in a North American population. J Hepatol 2012; 57: 736-42.

  5. Minami T, Kishikawa T, Sato M, Tateishi R, Yoshida H, Koike K. Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C. J Gastroenterol 2013; 48: 254-68.

  6. World Health Organization. Global Alert and Response: Hepatitis C. 2013. Available from: URL: http:// www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/ en/index4.html

  7. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-38.

  8. Ditah I, Ditah F, Devaki P, Ewelukwa O, Ditah C, Njei B, Luma HN, et al. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol 2014; 60: 691-8.

  9. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008; 48: 148-62.

  10. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liverrelated morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8: 280-8, 288.

  11. El-Kamary SS, Jhaveri R, Shardell MD. All-cause, liver-related, and non-liver-related mortality among hcv-infected individuals in the general US population. Clinical Infectious Diseases 2011; 53: 15.

  12. Di Martino V, Crouzet J, Hillon P, Thevenot T, Minello A, Monnet E. Long-term outcome of chronic hepatitis C in a population-based cohort and impact of antiviral therapy: a propensity-adjusted analysis. J Viral Hepat 2011; 18: 493-505.

  13. Guiltinan AM, Kaidarova Z, Custer B, Orland J, Strollo A, Cyrus S, Busch MP, et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol 2008; 167: 743-50.

  14. Allison RD, Conry-Cantilena C, Koziol D, Schechterly C, Ness P, Gibble J, Kleiner DE, et al. A 25-year study of the clinical and histologic outcomes of hepatitis C virus infection and its modes of transmission in a cohort of initially asymptomatic blood donors. J Infect Dis 2012; 206: 01.

  15. Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, et al. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology 2007; 50: 16-23.

  16. Duberg A-S, Torner A, Davisdottir L, Aleman S, Blaxhult A, Svensson A, Hultcrantz R, et al. Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. J Viral Hepatitis 2008; 15: 538-50.

  17. Kasahara A, Tanaka H, Okanoue T, Imai Y, Tsubouchi H, Yoshioka K, Kawata S, et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepatitis 2004; 11; 148-56.

  18. Kristiansen MG, Lochen M-L, Gutteberg TJ, Mortensen L, Eriksen BO, Florholmen J. Total and cause-specific mortality rates in a prospective study of community-acquired hepatitis C virus infection in northern Norway. J Viral Hepatitis 2011; 18; 237-44.

  19. Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, Yokosuka O. Long-term cohort study of chronic hepatitis C according to interferon efficacy. J Gastroenterol Hepatol 2012; 27; 291-9.

  20. Neal KR, Trent Hepatitis CSG, Ramsay S, Thomson BJ, Irving WL. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 2007; 56: 1098-104.

  21. Uto H, Stuver SO, Hayashi K, Kumagai K, Sasaki F, Kanmura S, Numata M, et al. Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study. Hepatology (Baltimore, Md) 2009; 50; 393-9.

  22. Vergniol J, Foucher J, Terrebonne E, Bernard PH, le BB, Merrouche W, Couzigou P, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 1979; 140: 1970-9.

  23. Yamasaki K, Tomohiro M, Nagao Y, Sata M, Shimoda T, Hirase K, Shirahama S. Effects and outcomes of interferon treatment in Japanese hepatitis C patients. BMC Gastroenterology 2012; 12: 139.

  24. Trapero-Marugan M, Mendoza J, Chaparro M, Gonzalez-Moreno L, Moreno-Monteagudo JA, Borque MJ, Moreno-Otero R. Long-term outcome of chronic hepatitis c patients with sustained virological response to peginterferon plus ribavirin. World J Gastroenterol 2011; 17; 493-8.

  25. Braks RE, Ganne-Carrie N, Fontaine H, Paries J, Grando-Lemaire V, Beaugrand M, Pol S, et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007; 13: 5648-53.

  26. Bruno S, Zuin M, Crosignani A, Rossi S, Zadra F, Roffi L, Borzio M, et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol 2009; 104; 1147-58.

  27. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G, Ascione A, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-87.

  28. Duarte-Rojo A, Veldt BJ, Goldstein DD, Tillman HL, Watt KD, Heimbach JK, McHutchison JG, et al. The course of posttransplant hepatitis c infection: Comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation 2012; 94: 27.

  29. Gomez EV, Rodriguez YS, Bertot LC, Gonzalez AT, Perez YM, Soler EA, Garcia AY, et al. The natural history of compensated HCV-related cirrhosis: A prospective long-term study. J Hepatol 2013; 58: 434-44.

  30. Mallet V, Gilgenkrantz H, Serpaggi J, Verkarre V, Vallet-Pichard A, Fontaine H, Pol S. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149: 399-403.

  31. Morgan TR, Ghany MG, Kim H-Y, Snow KK, Shiffman ML, De Santo JL, Lee WM, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52: 833-44.

  32. Pineda JA, Romero-Gomez M, Diaz-Garcia F, Giron-Gonzalez JA, Montero JL, Torre-Cisneros J, Andrade RJ, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005; 41: 779-89.

  33. Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, Arakawa Y, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carci noma development and improved survival. Annals of Internal Medicine 2005; 142: 105-14.

  34. Toshikuni N, Izumi A, Nishino K, Inada N, Sakanoue R, Yamato R, Suehiro M, et al. Comparison of outcomes between patients with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis. J Gastroenterology & Hepatology 2009; 24: 1276-83.

  35. Picciotto FP, Tritto G, Lanza AG, Addario L, De LM, Di Costanzo GG, Lampasi F, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459-65.

  36. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-93.

  37. Cardoso A-C, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, Boyer N, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52: 652-7.

  38. Lee M-H, Yang H-I, Lu S-N, Jen C-L, You S-L, Wang L-Y, Wang C-H, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: A community-based long-term prospective study. J Infect Dis 2012; 206: 15.

  39. Pacholczyk M, Lagiewska B, Lisik W, Tronina O, Wasiak D, Cieciura T, Chmura A. Liver transplantation for HCV cirrhosis; cautious optimism after 10 years of experience. Ann Transplant 2012; 17: 5-10.

  40. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013; 19: 850-8.

  41. Murphy SL, Xu J, Kochanek KD. Deaths: Final Data for 2010. National Vital Statistics Report 2013; 61; 1-117.

  42. Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med 2014; 161: 170-80.

  43. Hanafiah M, Groeger J, Flaxman AD, Wiersma ST. Global Epidemiology of Hepatitis C Virus Infection: New Estimates of Age-Specific Antibody to HCV Seroprevalence. Hepatology 2013; 57: 1333-42.

  44. Nelson KE. The impact of chronic hepatitis C virus infection on mortality. J Infect Dis 2012; 206: 461-3.

  45. Egger M, Smith G, Schneider M. Systematic reviews of observational studies. In: Egger M, Smith G, Altman D (eds.). Systematic Reviews in Health Care: Meta-analysis in Context. London: BMJ Publishing Group; 2010, p. 211-7.

  46. Colditz GA, Burdick E, Mosteller F. Heterogeneity in metaanalysis of data from epidemiologic studies: a commentary. Am J Epidemiol 1995; 142: 371-82.




2020     |     www.medigraphic.com